How to Join This Clinical Trial - NCTNCT03342144
Learn how to participate in this Not Specified trial studying an investigational therapy for Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell. Current status: ACTIVE_NOT_RECRUITING.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell
- Treatment Being Tested
- Investigational treatment
- Study Phase
- Not Specified - Research study
- Enrollment Status
- ACTIVE_NOT_RECRUITING
- Study Identifier
- NCTNCT03342144 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
Where Is This Clinical Trial Located?
This study is enrolling participants at 70 locations. Find a study site near you:
Clinical Research Site
Sankt Poelten, Niederoesterreich 3100 - Austria
Status: Contact for availability
Clinical Research Site
Graz, Steiermark 8010 - Austria
Status: Contact for availability
Clinical Research Site
Salzburg, 5020 - Austria
Status: Contact for availability
Clinical Research Site
Wien, 1140 - Austria
Status: Contact for availability
Clinical Research Site
Mutlangen, Baden-Wuerttemberg 73557 - Germany
Status: Contact for availability
Clinical Research Site
Stuttgart, Baden-Wuerttemberg 70174 - Germany
Status: Contact for availability
Clinical Research Site
Villingen-Schwenningen, Baden-Wuerttemberg 78052 - Germany
Status: Contact for availability
Clinical Research Site
Aschaffenburg, Bayern 63739 - Germany
Status: Contact for availability
Clinical Research Site
Aschaffenburg, Bayern 63739 - Germany
Status: Contact for availability
Clinical Research Site
Augsburg, Bayern 86150 - Germany
Status: Contact for availability
And 60 more locations available. Contact us to find the nearest participating site.